Wang Huiqin, Chen Weixia, Wang Ling, Li Faxin, Zhang Chunling, Xu Li
Department of Clinical Laboratory, Zaozhuang Municipal Hospital, Zaozhuang, Shandong 277102, P.R. China.
Department of Rheumatology, Zaozhuang Municipal Hospital, Zaozhuang, Shandong 277102, P.R. China.
Mol Med Rep. 2015 Apr;11(4):2761-6. doi: 10.3892/mmr.2014.3104. Epub 2014 Dec 17.
Fibroblast‑like synoviocytes (FLSs) have a pivotal role in the destruction of joints in rheumatoid arthritis (RA). Tumor necrosis factor receptor‑associated factor 6 (TRAF6) is a critical mediator in the inflammatory pathway and of the activity of osteoclasts. The aim of the present study was to investigate whether TRAF6 is involved in the progression of RA in mouse collagen‑induced arthritis (CIA) and human RA FLSs in vitro. In vivo mouse models were transfected with TRAF6 small interfering (si)RNA (siTRAF6) and TRAF6 inhibition was achieved in FLSs using an anti‑TRAF6 monoclonal antibody in vitro in order to assess the effects of TRAF6 inhibition on the migration and invasion of FLSs. Inhibition of TRAF6 using mouse specific siTRAF6 reduced the severity of arthritis and joint inflammation. Serum anti‑collagen II antibodies, matrix metalloproteinase (MMP)‑1, MMP‑3 and MMP‑9 were also inhibited in CIA mice by siTRAF6. The levels of MMPs produced by IL‑1β‑stimulated human RA‑FLSs were reduced by anti‑TRAF6 monoclonal antibody. TRAF6 blockade significantly suppressed the IL‑1β‑stimulated migration and invasion of human RA‑FLSs. These results support a role for TRAF6 in the pathogenesis of RA, and suggest that the TRAF6 blockade may be a potential strategy in the management of RA.
成纤维样滑膜细胞(FLSs)在类风湿性关节炎(RA)的关节破坏中起关键作用。肿瘤坏死因子受体相关因子6(TRAF6)是炎症通路和破骨细胞活性的关键介质。本研究的目的是调查TRAF6是否参与小鼠胶原诱导性关节炎(CIA)中RA的进展以及体外人RA-FLSs的情况。体内小鼠模型用TRAF6小干扰(si)RNA(siTRAF6)转染,体外使用抗TRAF6单克隆抗体在FLSs中实现TRAF6抑制,以评估TRAF6抑制对FLSs迁移和侵袭的影响。使用小鼠特异性siTRAF6抑制TRAF6可减轻关节炎的严重程度和关节炎症。siTRAF6还可抑制CIA小鼠血清中的抗胶原II抗体、基质金属蛋白酶(MMP)-1、MMP-3和MMP-9。抗TRAF6单克隆抗体可降低IL-1β刺激的人RA-FLSs产生的MMPs水平。TRAF6阻断显著抑制IL-1β刺激的人RA-FLSs的迁移和侵袭。这些结果支持TRAF6在RA发病机制中的作用,并表明TRAF6阻断可能是RA治疗的一种潜在策略。